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Abstract 
Background: Blood product transfusions are one of the most common procedures in the US. These 
transfusions are considered safe but there is still a risk of complications and mortality. The most 
common cause of transfusion related mortality being transfusion related acute lung injury (TRALI). TRALI 
is an acute lung condition that results in dyspnea, cough, and hypoxemia. It is hypothesized that TRALI is 
an antibody mediated phenomenon that is associated with female donors, as female and multiparous 
women have more HLA/HNA antibodies in their blood. This review is to investigate if there is increased 
mortality with the use of female blood products in male recipients. 
Methods: An exhaustive literature search using MEDLINE, Web of Science, and CINAHL via EBSCO-host 
was conducted. The following search terms were used: female, male, transfusion, mortality, donor, and 
pregnancy. Relevant articles were assessed for quality using the Grading of Recommendations, 
Assessment, Development and Evaluation (GRADE). 
Results: The literature search yielded 5 qualifying studies, all were retrospective cohort studies. The 
studies indicated that the use of female blood products did increase mortality among male recipients. 
Four of the 5 studies did show an increase in mortality among male recipients of female blood product 
donation. One study found increased mortality among male recipients specifically receiving multiparous 
female blood products. Another study reported increased mortality among male recipients receiving more 
than 2 units of female plasma. One study found no increased risk to male recipients receiving female 
blood products. 
Conclusion: Four of the 5 studies reviewed did show consistent results that men are negatively affected 
by use of female blood products. One study showed no increased risk. Further research is needed to 
determine the exact cause of increased male mortality and TRALI pathophysiology. In addition, 
investigations are needed to determine the best use of female blood products. These studies are just a 
start in truly understanding how sex mismatched blood transfusions affect patients’ bodies in the short 
and long term. 
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Abstract
Background: Blood product transfusions are one of the most common 
procedures in the US. These transfusions are considered safe but there 
is still a risk of complications and mortality. The most common cause 
of transfusion related mortality being transfusion related acute lung 
injury (TRALI). TRALI is an acute lung condition that results in 
dyspnea, cough, and hypoxemia. It is hypothesized that TRALI is an 
antibody mediated phenomenon that is associated with female donors, 
as female and multiparous women have more HLA/HNA antibodies in 
their blood. This review is to investigate if there is increased mortality 
with the use of female blood products in male recipients. 
Methods: An exhaustive literature search using MEDLINE, Web of 
Science, and CINAHL via EBSCO-host was conducted. The following 
search terms were used: female, male, transfusion, mortality, donor, 
and pregnancy. Relevant articles were assessed for quality using the 
Grading of Recommendations, Assessment, Development and 
Evaluation (GRADE). 
Results: The literature search yielded 5 qualifying studies, all were 
retrospective cohort studies. The studies indicated that the use of 
female blood products did increase mortality among male recipients. 
Four of the 5 studies did show an increase in mortality among male 
recipients of female blood product donation. One study found 
increased mortality among male recipients specifically receiving 
multiparous female blood products. Another study reported increased 
mortality among male recipients receiving more than 2 units of female 
plasma. One study found no increased risk to male recipients receiving 
female blood products. 
Conclusion: Four of the 5 studies reviewed did show consistent 
results that men are negatively affected by use of female blood 
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products. One study showed no increased risk. Further research is 
needed to determine the exact cause of increased male mortality and 
TRALI pathophysiology. In addition, investigations are needed to 
determine the best use of female blood products. These studies are 
just a start in truly understanding how sex mismatched blood 
transfusions affect patients’ bodies in the short and long term.  
Keywords: Transfusion, mortality, female donor, male, TRALI, blood, 
pregnancy  
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Increased Risk of Mortality with Female to 
Male Blood Product Transfusions
BACKGROUND
It is estimated that around 5 million Americans receive a blood 
transfusion annually and this consists of over 100 million red blood cell 
(RBC) units.1,2 These transfusions commonly consist of RBCs and fresh 
frozen plasma (FFP). Blood product transfusions are considered a 
generally safe procedure, however, the leading cause of transfusion 
mortality is transfusion-related acute lung injury (TRALI).3 It is 
estimated by the Food and Drug Administration (FDA) that 38% of 
transfusion related deaths were attributed to TRALI.4 TRALI is defined 
as an acute lung injury that can be distinguished by pulmonary edema 
resulting in decreased oxygen exchange and bilateral infiltrates on 
chest X-ray shortly after a blood transfusion.5 The exact cause of 
TRALI is undetermined3; however, the proposed pathophysiology is 
that anti-leukocyte antibodies, such as human leukocyte antigen (HLA) 
and human neutrophil antibodies (HNA), activate pulmonary 
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neutrophils in the transfusion recipient.5 This activation results in 
endothelial damage and pulmonary edema producing symptoms of 
dyspnea, cough, and hypoxemia.5,6
In those who develop TRALI, 70% of patients will require mechanical 
ventilation and ICU admission, with up to a 47% mortality rate. TRALI 
has been connected to all blood products including RBCs, FFP, and 
platelets.5 The highest incidence of cases and fatalities are associated 
with plasma rich products such as FFP.7 In up to 85% of TRALI cases, 
antibodies can be identified in blood products administered, specifically 
HNA and HLA Class 1 and 2 antibodies.5 TRALI has been implicated to 
be associated with transfusions from female blood product donors8, 
specifically multiparous females to male recipients.9 Pregnancy is a 
major immunizing event, and multiparous females create more 
antibodies during each pregnancy and the amount of HLA antibodies 
subsequently increase with parity.10 In Clippel et al,4 31% of 
multiparous women had HLA antibodies in their blood compared to 
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only 4.2% of nulliparous women screened. It is estimated that 17% of 
plasma units from female donors contain HLA antibodies.7 
This raises the question if blood products should be further screened 
for HLA/HNA antibodies specifically in multiparous women, or if blood 
products from females should still be even be used for transfusion. The 
UK implemented a policy in 2003 to eliminate female plasma products 
regardless of history of pregnancy11 in attempt to reduce the incidence 
of TRALI and therefore mortality. This systematic review is aimed at 
examining the link of increased mortality of blood product transfusions 
from female donors to male recipients.
METHODS
An exhaustive literature search using MEDLINE, Web of 
Science, and CINAHL via EBSCO-host was conducted. The following 
search terms were used: female, male, transfusion, mortality, donor, 
and pregnancy. The references from relevant articles were also 
searched. Included were studies that used female donor RBCs or FFP, 
male recipients of such products, and whose primary outcome was 
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mortality. Other inclusion criteria required studies to be published in 
English in the last 20 years and human only studies. Studies were 
excluded if they were published over 20 years ago or evaluated other 
outcomes not relevant to the clinical question. Relevant articles were 
assessed for quality using the Grading of Recommendations, 
Assessment, Development and Evaluation (GRADE).12 
RESULTS
The initial result of the search yielded 235 articles for 
review. After eliminating duplicates and screening results for relevant 
articles, there were a total of 5 articles that met eligibility criteria. All 
of the articles were retrospective cohort studies 9,2,13,14,7 (See Table 1.)
Caram et al
This retrospective cohort study9 consisted of 31 118 first 
time transfusion recipients from 6 major Dutch hospitals between May 
30, 2005 and September 1, 2015. All participants were in a no-donor-
mixture cohort where each participant received RBC transfusions from 
exclusively male donors, or exclusively all female donors with a history 
of pregnancy, or exclusively all female donors without a history of 
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pregnancy. Exclusion criteria included any patient included in a prior 
study measuring mortality after a female blood product transfusion to 
create an independent cohort.9
Donor information such as age, sex, and history of 
pregnancy were obtained via Sanquin, the national Dutch blood supply. 
All RBC transfusion products in the Netherlands are leukocyte reduced 
by filtration and ABO-RhD identically matched to recipient. The only 
outcome assessed was mortality at any time during follow up, which 
ended September 1st, 2015. This information was obtained through a 
nationally linked computer system which was considered complete due 
to the legal requirement for reporting all deaths to this system. 
Survival statistical analysis was performed via the Stata version 14.1 
and p values less than 0.05 were considered statistically significant.9 
Overall, 106 041 units of RBCs (76% from male donors, 
12% ever pregnant female, 12% never pregnant female) were 
transfused to 42 132 patients. The average recipient was 66 years old 
and received an average of 2 units RBCs. The hazard ratio (HR) of 
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males who were exposed to RBCs from ever-pregnant female donors 
was 1.13 (CI, 1.01-1.26, p value 0.03) and represented a statistically 
significant risk of mortality. The highest risk of mortality was seen in 
transfusion of RBCs from ever-pregnant females to male recipients 50 
years of age and younger. The risk of mortality from ever-pregnant 
female RBC transfusion was only increased with male recipients and 
did not result in an increased HR for female recipients. Transfusions 
from never-pregnant female donors did not confer a greater mortality 
risk in male or female recipients.9
Limitations to this study included information about history 
of pregnancy was missing for 44% of female donors and therefore only 
selected cases with complete data available were analyzed. The effect 
of increased mortality was only significant in patients less than 50 
years old which could make the findings tentative. Overall, this study 
demonstrated a significant increase in mortality of male recipients of 
multiparous donors.9
Middelburg et al 
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This cohort study14 evaluated mortality after blood product 
transfusions in relation to donor sex from April 2004 - May 2009 at the 
Leiden University Medical Center. All blood product and patient 
information was obtained from the Sanquin Blood Bank. Restrictions 
were applied to the study to allow the effect of donor sex to be 
analyzed. These restrictions included patients who received a single 
transfusion from a single donor, or patients who received multiple 
transfusions from only male or only female donors to allow unisex 
analysis. Mortality information was obtained from the nationally linked 
computer system to register deaths in the Netherlands. This is legally 
required and therefore the data is deemed complete and was 
monitored until April 2010.14
The cohort consisted of 11 211 patients who received a total 
of 96 009 transfusions. The study separated patients into two cohort 
groups from the  full cohort to be able to perform an accurate analysis. 
Single donor recipient-cohort were individuals who only received one 
transfusion and consisted of 1377 patients. Unisex recipient-cohort 
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consisted of 3806 patients, this cohort analyzed recipients given 
multiple transfusions from either the same sex or opposite sex but not 
mix sex transfusions. This is described further below.14   
The single donor recipient cohort was analyzed using 
Kaplan-Meir curves, log-rank tests and direct comparison of mortality 
over the five year span. The blood transfusions given to each patient is 
considered to be random since the sex of the donor blood was not 
known at time of transfusion. During the five year follow up 233 
patients died during that period with a median duration of 881 days.14
The unisex recipient cohort analyzed both blood transfusions 
given to same sex recipients and opposite sex recipients from the 
same or opposite sex donor. To correctly analyze this information the 
researchers used a propensity score calculated by a Cox regression 
model. This was calculated because there was a risk of confounding 
variables based on the total number of blood donations given to the 
medical facility by sex. The propensity score was calculated using all 
blood transfusion data within the five year span to estimate blood 
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product type and donor sex ratios. This information was then used to 
calculate sex matched and sex mismatched prognostic values (i.e. 
number of transfusions, recipient age, recipient sex). Of the 3806 
patients 847 died during the follow up period with an median duration 
of 773 days.14 
 The hazard ratio (HR) for the unisex recipient cohort 
receiving female blood product donation as opposed to male blood 
product donation was 1.1 (95% CI, 0.91-1.2). A HR of 1.2 (95% CI, 
0.98-1.5) in male recipients and 0.92 (95% CI, 0.73-1.2) in female 
recipients was also calculated. Surprisingly, this data shows that there 
may be a positive female donor/recipient relationship. The researchers 
further analyzed their sex mismatched data to identify any other 
possible relationships between donor sex and recipient sex.14
  HR for sex mismatched and sex matched transfusions in 
the unisex cohort was 1.2 (95% CI, 0.98-1.4).  Mortality among male 
recipients from female donations was increased in the single donation 
cohort. This was not seen among female recipients given male blood 
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products. The mortality also increased greatly when analyzed over 
time with a 5.8 death per 100 male recipients (95% CI, -0.70 to 12) 
over a 90 day period whom received female blood products.14    
This study demonstrated an increase in mortality among 
males recipients who receive female donors blood products. This 
increase in mortality was also demonstrated to increase over time. 
However overall blood transfusions from female donors does not 
appear to significantly increase mortality to both sexes when 
compared to blood transfusions from male donors as a whole.14 
This study has the strength that allocation of blood products 
was completely random and not influenced by donor sex and had no 
confounding variables. The study also is able to demonstrate the real 
impact that different types of blood products from different sexes 
would pose to same and different sex recipients. Many other studies 
focus on plasma rich products but this study in particular used all 
blood products types. Weaknesses of this study is lack of power these 
results could still be explained by chance although that is unlikely. Also 
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researchers were unable to completely study the exact cause of death 
for each patient. More studies are needed to determine if the increased 
mortality is due to chance or other biological causes.14   
Chasse et al 
This longitudinal cohort study2 investigated the effect of 
donor sex on RBC transfusion recipient survival from October 25, 2006 
to December 31, 2013. Information of the blood donors was obtained 
from Canadian Blood Services and 4 participating academic hospitals 
in Canada. To be included in the study, recipients of any age had to 
have received at least one RBC transfusion during the above dates and 
have valid health insurance. Mortality data was gathered from the 
Ontario Registered Persons Database. Data was analyzed based on a 
Cox proportional hazards regression model to account for cumulative 
RBC transfusions over time and average follow up was 2.3 years. All 
RBC units were leukoreduced before transfusion.2 
The cohort consisted of 30 503 recipients, 80 755 blood 
donors, and 187 960 units of RBCs transfused. The average age of 
patients was 69, 52.1% were female, and received an average of 3 
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units RBCs. A Charlson Comorbidity Index of at least 5 was present in 
20.7% of patients. Death occurred in 43% of recipients. Donors of 
opposite sex was associated with an increased mortality. There was an 
8% increase risk of death in male recipients for each additional RBC 
unit transfused from a female donor compared to a male donor (HR 
1.08; CI, 1.06-1.09, P <0.001). The decreased survival associated 
with female donors was observed across all Charlson Comorbidity 
Index subgroups. In absolute terms, the 1-year mortality rate of 
36.4% in recipients of 6 female RBC units, would result in an absolute 
risk reduction in mortality of 9.3% (CI, 8.3%-10.4%) when compared 
to male donor transfusions. This is reported as a number needed to 
treat of 11.2
Blood donor data was masked from the prescribing 
physicians and the female donor exposure being randomly distributed 
to recipients allowed this study to have characteristics of a randomized 
clinical trial such as allocation concealment and double-blinding. RBC 
transfusions from female donors was statistically significantly 
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associated with an increased mortality of recipients. This study 
suggests that clinical trials are warranted as this appears to affect 
transfusion recipient outcome.2 
Tynell et al
This retrospective cohort study7 evaluated short term mortality 
after plasma transfusions from female donors. The information from 
this study was gathered from The Scandinavian Donations and 
Transfusions (SCANDAT) database from 30 Swedish hospitals. 
Eligibility criteria included required known birthdate, blood type, 
recipient to be at least 18 years old, and had their first allogeneic 
plasma transfusion between January 1, 1990 and December 31, 2002. 
Patients were excluded from the study if they had an organ or 
hematopoietic stem cell transplant on or before the date of their first 
plasma transfusion.7
The cohort of 92 565 patients were followed for 14 days 
after their first plasma transfusion to identify any deaths from any 
cause. The median age of the cohort was 70 years old with 55% of 
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patients being male. A Poisson regression model was used to estimate 
the relative risk (RR) of death in patients who received a plasma 
transfusion from a female donor. At least one unit of female plasma 
was given to 68% of patients. These same patients also required a 
larger number of plasma and RBC units. A total of 7800 (8.43%) 
recipients died during follow up, 8.85% in patients exposed to female 
plasma, and 7.53% in the unexposed patients.7
RRs were calculated by using patients who were exposed to 
female donor plasma and patients who were not exposed. The patients 
were of similar age, sex, and received the same volume of plasma at 
the same hospital within the same calendar year. For patients receiving 
one to two units of female plasma there was no evidence of increased 
risk with RRs of 1.01 and 1.00 respectively. Patients who received 3 to 
4 units had RR of 1.16 (CI, 1.06-1.27, p value 0.002) showing a 
significant increase in mortality compared to patients who received 
male only plasma. The highest incidence of mortality was seen in 
patients who received 5 or more units of female plasma and whose 
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death after diagnosis was attributed to respiratory or circulatory 
morbidity or adverse reaction, with a RR of death of 1.72 (CI, 
1.29-2.29, p value 0.0002). When comparing this subset of patients by 
the recipients sex, the RR of death of male recipients was 1.80 (CI, 
1.25-2.60, p value 0.002) compared to the RR of 1.30 (CI, 1.10-1.52, 
p value 0.002) of their female counterparts.7
By applying the observed RR of comparison of exposure to 
female plasma in patients whose discharge diagnosis death was 
attributed to respiratory or circulatory morbidity, or adverse reactions 
it is estimated that there would be 8.8 fewer deaths for every 10 000 
patients transfused if male only plasma was used. This study 
demonstrated a possible volume effect as the risk of mortality was 
seen in patients who received 3 or more units of plasma. Strengths of 
this study included a large sample size over twelve years which helped 
ensure generalizability and provides risk estimates with high precision.
7
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Limitations include possible confounding factors such as 
critically ill patients receiving more units of plasma are more likely to 
receive plasma from a female donor. Due to this being a retrospective 
study, the possibility that there was a non random distribution of male 
and female units among patients with different prognoses cannot be 
ruled out. There was also insufficient data to investigate the donor 
parity status. Overall, this study concludes that plasma transfusions 
from female donors confers a short-term survival disadvantage on 
male recipients.7  
Desmarets et al
A retrospective cohort study13 was performed by the French 
Blood Services and two university hospitals to examine the relationship 
of donor sex of transfused RBCs on 1 year survival in patients who 
underwent cardiac surgery. The national blood service in France has a 
register of all transfused blood units and  transfusion recipients. Data 
was gathered from this database to obtain information such as donor 
sex, while recipient data was gathered from the university hospitals. 
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Eligibility criteria included adult patients who were transfused for the 
first time between January 2007 and December 2011. Patients must 
have also undergone cardiac surgery during this time, the most 
common surgery in the cohort was valvular replacement.13 
The cohort included 2715 patients with the median age 
being 72, of which 63.1% were male patients. The median number of 
units transfused was 2 per patient: 17.8% of patients received only 
products from the same sex, 17.9% received products from donors of 
the opposite sex, while 64.3% of patients received a partial sex match. 
Males had a higher rate of receiving sex-matched blood products than 
females. The rate of sex-mismatch increased when patients required 5 
or more units of RBCs.13
 This study found that patients had no increased risk of 
mortality by receiving RBCs from opposite sex donors. Males who 
received female only blood products had a HR of 0.98 (CI, 0.59-1.63) 
while males who received a mix of female and male RBCs had an 
increased HR of 2.14 (1.52-3.03). This effect was more pronounced in 
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female RBC recipients who were transfused with male only RBCs with a 
HR of 2.03 but was not found significant (CI, 0.87-4.43; p value 0.17).
13 
 The limitations of this study include a possible selection 
bias as the linkage between the transfusion register and the hospital 
discharge abstracts were only able to link about 80% of the initial 
population. They also used diagnosis related groups (DRGs) to 
measure patients comorbidities, clinical setting, and underlying illness. 
DRGs are used to examine the use of hospital resources and were not 
designed to perform this type of study and do not provide a precise 
description of the patient’s condition, however mortality was still able 
to be measured. Overall, this study concluded that RBC transfusions 
from opposite sex donors is safe and there was no significant effect in 
male recipients.13
DISCUSSION 
Four of these studies9,2,14,7 have demonstrated that there is 
a link between female blood donors and increased mortality among 
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male recipients. Each researched a different sub group, ie. 
multiparous, plasma, and RBC products but overall there was an 
associated increase in mortality when males receive female blood 
products. There is an obvious link that antibodies play a role in these 
reactions but the studies were not able to definitively state the overall 
cause because the pathophysiology behind these reactions is so 
complex.  
Caram et al9 found increased risk with use of ever pregnant 
females blood products to male recipients with a hazard ratio (HR) of 
1.13 (CI, 1.01-1.26, p value 0.03). This data gives merit to the 
hypothesis that pregnancy can create harmful antibodies in female 
blood products. Could then a practice of not using ever-pregnant 
female blood in transfusion medicine be feasible? The UK believes in 
this risk and recently created a policy advising to stop the use of 
female blood products in transfusions.11  Middleburg et al14 also found 
that mortality could even be increased over a 90 day period when 
males received female blood products with 5.8 death per 100 male 
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recipients (95% CI, -0.70 to 12). Should there then be more follow up 
after transfusions among recipients regardless of type of transfusion? 
Chasse et al2 did contribute a 8% increase risk of death in male 
recipients for each additional RBC unit transfused from a female donor 
compared to a male donor (HR 1.08; CI, 1.06-1.09, P <0.001). 
The highest incidence of mortality was seen in patients who 
received 5 or more units of female plasma and whose death after 
diagnosis was attributed to respiratory or circulatory morbidity or 
adverse reaction, with a RR of death of 1.72 (CI, 1.29-2.29, p value 
0.0002). When comparing this subset of patients by the recipients sex, 
the RR of death of male recipients was 1.80 (CI, 1.25-2.60, p value 
0.002) compared to the RR of 1.30 (CI, 1.10-1.52, p value 0.002) of 
their female counterparts.7    Understanding the cause of death would 
ultimately help determine the exact cause of increased mortality. 
Tynell et al7 did not find it feasible to monitor if TRALI was the cause of 
death because there is no unique diagnosis for TRALI or death code, 
however, 1477 patients died with respiratory or cardiac complications 
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which suggests possible TRALI. More detailed health records are 
needed among individuals who suffer from an adverse event after 
transfusion to better understand this phenomenon.
Because these reactions are so complex it would be hard at 
this time to make recommendations to change the current practice of 
blood transfusions. From these studies it is apparent that plasma rich 
products pose a greater risk of mortality than plasma poor.7 However, 
plasma poor products such as RBCs are more common transfusion 
components than plasma rich products.14 Female donors make up a 
large portion of the donor pool and the feasibility and implications to 
completely exclude females needs to be investigated. 
Possible avenues to protect patients from these reactions 
were suggested by Clippel et al10 including creating new screening 
methods to reduce the likelihood of adverse reactions by screening for 
specific antibodies for example HLA/HNA antibodies.  Kent et al11 also 
suggested instead of using female blood products for transfusion, 
using these blood products for productions of other products not used 
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acutely. The point was also made that there would be 8.8 fewer deaths 
for every 10 000 patients transfused if male only plasma was used as 
compared to exposure to female plasma in patients who death was 
contributed to respiratory or circulatory morbidity.7 
Desmartes et al13 did not find increased risk associated with 
female blood donors although this study did have significant selection 
and author bias which makes the quality of this evidence very low. Due 
to these biases within the study we do not know how reliable this data 
is when examining the risks of using female blood products.   
CONCLUSION
Based on recent studies, there appears to be an increased 
risk of mortality among men who are transfused with female blood 
products. This increased risk is more associated with plasma rich 
products like FFP, however it is still seen in RBC type transfusion. The 
investigators hypothesized that this phenomenon is due to HLA/HNA 
antibodies in female donors, particularly multiparous, reacting in male 
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recipients. This antibody reaction is likely contributing to mortality via 
TRALI, however the exact pathophysiology is still unknown. 
More research is needed to investigate exactly what is 
causing these blood reactions including studies involving HLA/HNA and 
other associated antibodies. Females donations contribute to a large 
majority of transfusion products, however,  implications of removing 
female blood products from the donor pool need to be considered. 
More studies, specifically RCTs, are needed to determine the risk 
associated with using female blood products and a way in which we 
can reduce mortality risk to male recipients.  
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Table 1: Quality Assessment of Reviewed Articles
Study
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Crite
ria
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ness
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ency
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Publica
tion 
bias
Caram et 
al
Cohor
t
 Not 
Serious     
Not 
Serious 
 Not 
Serious
Not 
Serious
Unlikel
y
    N/
A
Low
Middelbu
rg et al
Cohor
t
Not 
Serious
Not 
Serious
Not 
Serious
Not 
Serious
Unlikel
y 
N/A Low
Chasse et 
al
Cohor
t
Not 
Serious
Not 
Serious
Not 
Serious
Not 
Serious 
Unlikel
y
N/A Low
Tynell et 
al
Cohor
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Serious
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Serious 
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N/A Low 
Desmaret
s et al
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Low
a The Desmatets et al study had 2 authors who worked for the French Blood Services 
who supported the study             
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